Hungarian drugmaker Gedeon Richter has announced that the European Commission has granted marketing authorization for the biosimilar denosumab products Junod and Yaxwer.

DelveInsight's Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Detailed price information for Gedeon Richter Ltd (RGEDF) from The Globe and Mail including charting and trades.

See the latest Chemical Works of Gedeon Richter PLC stock price (RICHTER:XBUD), related news, valuation, dividends and more to help you make your investing decisions.

Around 4,500 women in the UK will be eligible for treatment with Gedeon Richter's once-daily oral therapy Ryeqo, after NICE backed the GnRH antagonist to treat heavy menstrual bleeding associated ...

Romania’s Ambassador to Hungary, Gabriel Şopandă, is a well-known face among Budapest’s diplomatic corps. As his term in ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that the Committee for Medicinal Products for Human Use ...

Review the current Chemical Works of Gedeon Richter PLC (RICHTER:XBUD) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if RICHTER is the best investment ...